Clustering of rare peptide segments in the HCV immunome

Self/Nonself - Immune Recognition and Signaling

Volumn 1, Issue 2, 2010, Pages 154-162

  Stufano, Angela ^a   Capone, Giovanni ^a   Pesetti, Barbara ^a   Polimeno, Lorenzo ^a   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti HCV vaccine; B cell epitopes; HCV; Human proteome; Low similarity peptides; Nonself HCV peptides

Indexed keywords

ANTIBODY; ANTIGEN; EPITOPE; HEPATITIS C VACCINE; PEPTIDE VACCINE; PROTEOME;

AMINO ACID SEQUENCE; ARTICLE; DATA BASE; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFORMATION; NONHUMAN;

EID: 77954888680     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.1.2.11391     Document Type: Article

References (52)

1. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity and mortality. BMC Public Health 2009; 9:34.
2. Schmitz U, Tan SL. NS5A.from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov 2008; 3:77-92.
3. Lukavsky PJ. Structure and function of HCV IRES domains. Virus Res 2009; 139:166-71.
4. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93:15394-9.
5. Chang DY, Shin EC. Immune-based therapy for chronic hepatitis C. J Leukoc Biol 2009; 86:33-9.
6. Mittelman A, Lucchese A, Sinha AA, Kanduc D. Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome. Int J Cancer 2002; 98:741-7.
7. Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the antiDsg3 MAb 5H10. J Transl Med 2004; 2:43.
8. Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 2004; 25:1865-71.
9. Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, Kanduc D. Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. J Invest Dermatol 2004; 123:670-5.
10. Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer 2004; 111:720-6.
11. Lucchese A, Willers J, Mittelman A, Kanduc D, Dummer R. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity. J Immunol 2005; 175:7009-20.
12. Willers J, Lucchese A, Mittelman A, Dummer R, Kanduc D. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol 2005; 14:543-50.
13. Stufano A, Kanduc D. Proteome-based epitopic peptide scanning along PSA. Exp Mol Pathol 2009; 86:36-40.
14. Kanduc D, Lucchese A, Mittelman A. Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology. Peptides 2001; 22:1981-5.
15. Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 2009; 22:639-46.
16. Lucchese G, Stufano A, Kanduc D. Proteome-guided search for influenza A B-cell epitopes. FEMS Immunol Med Microbiol 2009; 57:88-92.
17. Kanduc D, Lucchese A, Mittelman A. Non-redundant peptidomes from DAPs: towards "the vaccine"? Autoimmun Rev 2007; 6:290-4.
18. Kanduc D. Correlating low-similarity peptide sequences and allergenic epitopes. Curr Pharm Des 2008; 14:289-95.
19. Kanduc D. Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. In Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease A. Sigalov, Ed., Landes Bioscience, Austin TX, USA 2008; 198-207.
20. Kanduc D. Self-nonself peptides in the design of vaccines. Curr Pharm Des 2009; 15:3283-9.
21. Kanduc D, Tessitore L, Lucchese G, Kusalik A, Farber E, Marincola FM. Sequence uniqueness and sequence variability as modulating factors of human antiHCV humoral immune response. Cancer Immunol Immunother 2008; 57:1215-23.
22. Polimeno L, Mittelman A, Gennero L, Ponzetto A, Lucchese G, Stufano A, et al. Sub-epitopic dissection of HCV E1315-328HRMAWDMMMNWSPT sequence by similarity analysis. Amino Acids 2008; 34:479-84.
23. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005; 3:91.
24. May AC. Percent sequence identity; the need to be explicit. Structure 2004; 12:737-8.
25. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12:1255-65.
26. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33:703-7.
27. Sato A, Ida N, Ishikawa M, Tanahashi K, Nakamura H, Sho Y, et al. A sensitive serodiagnosis of hepatitis C virus (HCV) infection with two non-fused peptides: comparison of antibody responses detected with a newly developed assay and a commercial second-generation test. Microbiol Immunol 1993; 37:295-304.
28. Zhang ZX, Sönnerborg A, Sällberg M. Antigenic structure of the hepatitis C virus envelope 2 protein. Clin Exp Immunol 1994; 98:382-7.
29. Sällberg M, Rudén U, Wahren B, Magnius LO. Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin Exp Immunol 1993; 91:489-94.
30. Carlos MP, Yamamura Y, Vu Q, Conzen K, Anderson DE, Torres JV. Humoral immunity to immunodominant epitopes of hepatitis C virus in individuals infected with genotypes 1a or 1b. Clin Immunol 2004; 111:22-7.
31. Pirisi M, Fabris C, Toniutto P, Vitulli D, Soardo G, Falleti E, et al. Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma. Cancer Res 1995; 55:111-4.
32. León P, López JA, Elola C, Lee SR, Calmann M, Echevarría JM. Use of overlapping synthetic peptides to characterize samples from blood donors with indeterminate results to hepatitis C virus core antigen. Vox Sang 1998; 75:32-6.
33. Wang YF, Brotman B, Andrus L, Prince AM. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis 1996; 173:808-21.
34. Ching WM, Wychowski C, Beach MJ, Wang H, Davies CL, Carl M, et al. Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. Proc Natl Acad Sci USA 1992; 89:3190-4.
35. Tobler LH, Busch MP, Wilber J, Dinello R, Quan S, Polito A, et al. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion 1994; 34:130-4.
36. Machida A, Ohnuma H, Tsuda F, Munekata E, Tanaka T, Akahane Y, et al. Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein. Hepatology 1992; 16:886-91.
37. Rodríguez-López M, Riezu-Boj JI, Ruiz M, Berasain C, Civeira MP, Prieto J, et al. Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. J Gen Virol 1999; 80:727-38.
38. Jolivet-Reynaud C, Dalbon P, Viola F, Yvon S, ParanhosBaccala G, Piga N, et al. HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. J Med Virol 1998; 56:300-9.
39. Akatsuka T, Donets M, Scaglione L, Ching WM, Shih JW, Di Bisceglie AM, et al. B-cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies. Hepatology 1993; 18:503-10.
40. Siemoneit K, Cardoso Mda S, Koerner K, Wölpl A, Kubanek B. Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1. Clin Exp Immunol 1995; 101:278-83.
41. Shirai M, Arichi T, Chen M, Masaki T, Nishioka M, Ikeda K, et al. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J Immunol 1999; 162:568-76.
42. Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 2007; 88:2991-3001.
43. Olenina LV, Nikolaeva LI, Sobolev BN, Blokhina NP, Archakov AI, Kolesanova EF. Mapping and characterization of B cell linear epitopes in the conservative regions of hepatitis C virus envelope glycoproteins. J Viral Hepat 2002; 9:174-82.
44. Wienhues U, Ihlenfeldt HG, Seidel C, Schmitt U, Kraas W, Jung G. Characterization of a linear epitope in the nonstructural region 4 of hepatitis C virus with reactivity to seroconversion antibodies. Virology 1998; 245:281-8.
45. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3. J Clin Microbiol 1993; 31:1493-503.
46. Rosa C, Osborne S, Garetto F, Griva S, Rivella A, Calabresi G, et al. Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4-NS5 synthetic peptide for serodiagnosis. J Virol Methods 1995; 55:219-32.
47. Quiroga JA, Martin J, Pernas M, Pardo M, Herrero M, Castillo I, et al. Evidence of subtype-specific antibodies to antigenic epitopes in the NS5 region of hepatitis C virus in the circulation of patients with chronic hepatitis C. Clin Diagn Lab Immunol 1994; 1:545-51.
48. Petit MA, Jolivet-Reynaud C, Peronnet E, Michal Y, Trépo C. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope. J Biol Chem 2003; 278:44385-92.
49. Wu CH, Yeh LS, Huang H, Arminski L, Castro-Alvear J, Chen Y, et al. The protein information resource. Nucleic Acids Res 2003; 31:345-7.
50. Kusalik A, Bickis M, Lewis C, Li Y, Lucchese G, Marincola FM, et al. Widespread and ample peptide overlapping between HCV and Homo sapiens proteomes. Peptides 2007; 28:1260-7.
51. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-73.
52. Pol S, Thiers V, Nousbaum JB, Legendre C, Berthelot P, Kreis H, et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in emodialyzed patients and kidney recipients. Gastroenterology 1995; 108:581-3